<DOC>
	<DOC>NCT02044692</DOC>
	<brief_summary>The objective of this study is to evaluate the long term safety and efficacy of once weekly dosing of idurasulfase-beta 0.5mg/kg administered in Hunter Syndrome(Mucopolysaccharidosis II) Patients</brief_summary>
	<brief_title>The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Patients who have a diagnosis of Hunter syndrome(Mucopolysaccharidosis II). Patients who are administered idurasulfasebeta or willing to be administered idurasulfasebeta. Patient's parent(s), or patient's legal guardian must have given voluntary written consent to participate in the study. Patients who have participated in any other blind clinical trials. Patient who cannot be tracked about safety. Patients who are judged disqualified to participate clinical trials by investigator for other causes.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>Mucopolysaccharidosis II</keyword>
	<keyword>Hunterase</keyword>
</DOC>